Group of 77 and South Centre convening on the Future of Antimicrobial Resistance Response in Developing Countries
Meeting Report
October 2024
On 25 September, the South Centre with the Group of 77 and China discussed solutions for tackling Antimicrobial Resistance and ensuring access to antibiotics and diagnostics.
Statement of the South Centre to the High-Level Meeting on AMR
September 2024
The South Centre is committed to support developing countries in tackling antimicrobial resistance. We welcome the opportunity to speak to this Assembly and add our voice to the call for urgent action to tackle this global threat. This year must mark the turning point in the collective efforts backed by new commitments and targets.
AMR in Aquaculture: Enhancing Indian Shrimp Exports through Sustainable Practices and Reduced Antimicrobial Usage
By Robin Paul
This study on Antimicrobial Resistance (AMR) in Indian shrimp farming underscores its critical impact on public health, environmental sustainability, and economic viability. The global scenario with many export rejections on account of persistent residues of antibiotics, reiterate that antimicrobial use in aquaculture, demands urgent global attention.
In the Indian context, the shrimp industry grapples with a delicate balance between production demands and long-term shrimp health. Sustainable practices, including responsible antimicrobial use, are crucial for economic viability, given the industry’s reliance on specific markets like the United States, EU and China.
Sustainable aquaculture emerges as a pivotal solution, supported by government policies and a gradual industry shift towards best practices. However, challenges persist, requiring a comprehensive approach to balance economic interests with environmental conservation. The key challenges remain the large number of small stakeholders and huge geographical spread of farms which make implementation of regulations and sharing of best practices difficult. Traceability and certification programs can play a key role in promoting responsible aquaculture, ensuring transparency and accountability in the supply chain. Technological innovations, including block chain can offer efficient solutions for traceability.
The collaborative action suggested emphasizes the role of government bodies, regulatory agencies, industry players, researchers, and consumers in addressing AMR. Clearer implementable regulatory frameworks aligned with economic and environmental priorities are essential. Looking ahead, the study envisions a future where the blue economy is sustainable not just for the industry’s success but also to protect the wider environment. By enhancing domestic market presence and fostering collaboration with importing countries, the Indian industry can overcome the multiple challenges raised by AMR in shrimp aquaculture.
The United Nations High-level Meeting on Antimicrobial Resistance on September 26, 2024: Uniting to Enable the Global Response to the Silent Pandemic
By Viviana Munoz Tellez
The “silent pandemic” of antimicrobial resistance (AMR) is getting worse and requires a global response built on international cooperation and solidarity. On 26 September 2024, the United Nations (UN) General Assembly will hold a second High Level Meeting on Antimicrobial Resistance. The dedicated meeting is a new effort to bring urgent attention by leaders for increased action on the growing risk of untreatable infections becoming more widespread and of increasing mortality.
The Future of Antimicrobial Resistance Response in Developing Countries Breakfast Meeting
co-organized by the Permanent Mission of the Republic of Uganda to the United Nations and the South Centre
25 September 2024
109 West 39th Street
(2nd Floor, Sydney Room)
Bryant Park, New York, 10018
Ongoing Negotiation of a Pandemic Accord: South Centre’s Intervention to WHO Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response
18 September 2024
We are pleased to be participating in the morning open sessions of the World Health Organization Intergovernmental Negotiating Body’s 11th meeting for the negotiation of a pandemic instrument. See our intervention on 18 September 2024.
Designing a scientific panel on AMR: Lessons from climate change policy
co-organized by Global Strategy Lab, AMR Policy Accelerator, and the South Centre
A discussion on design principles for a successful scientific panel on AMR, including lessons from the Intergovernmental Panel on Climate Change.
11 September 2024
Catalyzing Policy Action to Address Antimicrobial Resistance: Next Steps for Global Governance
By Anthony D. So
The United Nations General Assembly has taken up Antimicrobial Resistance (AMR) twice in the past decade, but the follow-through on commitments and financing of both Global and National Action Plans on AMR have lagged considerably behind the policymaker pronouncements. The need to update the intersectoral approach to the Global Action Plan on Antimicrobial Resistance requires urgent attention if measurable progress is to be made in tackling this One Health challenge. This paper identifies where progress must pick up and outlines how intersectoral action might catalyze needed next steps.
Financial Support for Civil Society Advocacy during World Antimicrobial Resistance Awareness Week (WAAW) 2024
The South Centre invites applications from civil society organizations and research institutions from developing countries for limited financial funding to design and launch or extend impactful advocacy campaigns that engage local government, communities and media to address antimicrobial resistance.
The scope of the campaigns can be human health, the human-animal interface, use of antimicrobials in food production systems, the role of the environment in the transmission and spread of AMR, and the link of Universal Health Coverage with AMR.
The campaigns should take place around the World AMR Awareness Week 2024. The WAAW 2024 theme is “Educate. Advocate. Act now”, and it will be held from 18 to 24 November 2024.
Deadline: 1 October 2024
Equity and Pandemic Preparedness: Navigating the 2024 Amendments to the International Health Regulations
By Nirmalya Syam
The amendments to the International Health Regulations (2005) (IHR) agreed upon in May 2024 are important for strengthening global health emergency preparedness and response. The negotiations resulted in the IHR amendment now recognizing the importance of equity, including equitable access to health products, enhancing IHR core capacities, and mobilizing financing. The amendments note the role of the World Health Organization (WHO) in facilitating timely access to necessary health products by removing barriers and supporting local production and distribution. However, the WHO authority to effectively act in those areas is limited. The IHR as amended will establish a Coordinating Financial Mechanism to provide predictable and sustainable financing for its implementation, particularly in developing countries.
Despite some advancements, the amendments fall short of imposing concrete obligations on developed countries to facilitate timely access to health products and financial support and transfer of technology to developing countries. Overall, the amended IHR represent a significant step toward a more equitable global health framework, setting a precedent for future international health instruments, including the proposed pandemic treaty.
Vacancy Announcement:
Consultant / Antimicrobial Resistance
Duty Station: Geneva, Switzerland or remote
The South Centre is seeking to fill a consultancy position to support its activities in the area of tackling antimicrobial resistance in developing countries.
Negotiating Health and Autonomy: Data Exclusivity, Healthcare Policies and Access to Pharmaceutical Innovations
By Henrique Zeferino De Menezes, Julia Paranhos, Ricardo Lobato Torres, Luciana Correia Borges, Daniela De Santana Falcão and Gustavo Soares Felix Lima
This paper analyzes the debate over the international dissemination of data exclusivity as a form of protection for clinical trial data. This is a critical demand for pharmaceutical companies seeking larger market shares and longer periods of monopoly in order to recover investments in research and development and greater profitability. However, this is a sensitive issue with economic and social repercussions for developing countries that adopt this protection regime. This paper highlights critical issues for the political economy of innovation and presents a review of empirical studies that show that data exclusivity delays the entry of generic drugs into the market, increasing prices and reducing access. At the same time, its adoption has no benefits because there are no positive effects on internal technological innovation, nor reduction of the “International drug lag”, nor the development of drugs for specific epidemiological demands.
